Make your money go further for just 25p per day

Hikma (HIK)

Market: FTSE · Sector: Pharmaceuticals & Biotechnology

PREMIUM
Portfolio

Income Boosters: clinical growth and takeover rumours

25/02/2021
Solid results support an increase in dividends for these high-yielders

More on Hikma


PREMIUM
Portfolio

Income Boosters: active management beats the FTSE in 2020

12/01/2021
PREMIUM
Portfolio

Income Boosters: Stable dividends supported by strong cash flow

06/11/2020
PREMIUM
Portfolio

Income Boosters: Dividends reassure but risks remain

26/08/2020
PREMIUM
Portfolio

National Grid takes hit from COVID-19 but confirms dividend rise

25/06/2020
PREMIUM
Portfolio

Coronavirus impact: light at the end of the tunnel for dividends?

07/05/2020
PREMIUM
Portfolio

Results Roundup: high yielders still delivering

06/03/2020
PREMIUM
Portfolio

Our Income Boosters deliver a FTSE-beating 5.2% yield in 2020

08/01/2020
PREMIUM
Portfolio

Dividend diamonds: our income stocks continue to deliver solid results

19/11/2019
PREMIUM
Portfolio

Our income portfolio is delivering market-beating dividend growth

18/09/2019
Company Insights

FTSE shuffle: September promotions and demotions

29/08/2019
PREMIUM
Company Insights

Dividend dogs vs diamonds: Part 3 – marvellous mid-caps

05/06/2019
Company Insights

FTSE shuffle: who’s up and down in June?

31/05/2019
Company Insights

Batten down the hatches – it’s time to get defensive

12/02/2019
PREMIUM
Portfolio

Hikma: Delivering inflation-proof income

05/02/2019